Status:
COMPLETED
Safety and Efficacy Study of Guaifenesin and Pseudoephedrine for Symptomatic Therapy to Treat Acute RTI
Lead Sponsor:
Reckitt Benckiser Inc.
Conditions:
Acute Upper Respiratory Track Infection
Eligibility:
All Genders
18-75 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to determine if treatment with Mucinex D lowers the use of antibiotics in the treatment of upper respiratory infection when compared to placebo
Eligibility Criteria
Inclusion
- patients aged 18 to 75 yrs of age presenting at a clinical site with symptoms diagnostic for an acute upper respiratory tract infection within the last 5 days
Exclusion
- patients who had chronic, recurring respiratory signs and symptoms due to conditions such as chronic allergic rhinitis, chronic sinusitis or chronic bronchitis which in the investigator's opinion, confounded interpretation of symptom ratings for the acute upper respiratory infection. Also excluded were patients with a fever greater than 101 degrees F.
Key Trial Info
Start Date :
October 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2010
Estimated Enrollment :
1179 Patients enrolled
Trial Details
Trial ID
NCT01202279
Start Date
October 1 2009
End Date
July 1 2010
Last Update
December 30 2020
Active Locations (24)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinical Research Advantage, Inc.
Mesa, Arizona, United States, 85203
2
Med Center
Carmichael, California, United States, 95608
3
Research Center of Fresno, 3636 N. First Street, Suite 141
Fresno, California, United States, 93726
4
Coastal Medical Research Group, Inc., 47 Santa Rosa Street
San Luis Obispo, California, United States, 93405